SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

  • Views:

    Views Icon 1029
  • Likes:

    Heart Icon 1

Overview

Full programme

  • Views:

    Views Icon 1029
  • Likes:

    Heart Icon 1

Overview

Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders. 

 

The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.

 

In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities.  Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

  • Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
  • Apply findings from clinical trials into clinical practice
  • Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
  • Evaluate the safety and cardiorenal benefits of glucose-lowering agents
  • Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists
  • Endocrinologists

Series overview

Part 1

State of the Art 1

6 sessions

  • Welcome and Introduction

    Watch now
  • SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started

    Watch now
  • SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection

    Watch now
  • SGLT2 Inhibitors in Cardiology Indications: The Data

    Watch now
  • SGLT2 Inhibitors in Chronic Kidney Disease: The Data

    Watch now
  • Panel Discussion

    Watch now

Part 2

SGLT2 Inhibitors in Heart Failure: A Practical Approach

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

4 sessions

  • Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm

    Watch now
  • SGLT2 Inhibitors: Safety Considerations

    Watch now
  • How to Use SGLT2 Inhibitors in Daily Practice

    Watch now
  • Panel Discussion

    Watch now

Part 3

Meet The Expert: Implications for Clinical Practice - Breakout 1

Totality of Evidence for the Cardiorenal Patient - discussion with Alice Cheung and Andrew Coats. Session supported by an unrestricted grant from AstraZeneca

2 sessions

Part 4

Meet The Expert: Implications for Clinical Practice - Breakout 2

SGLT2i and QoL Improvement - discussion with Shelley Zieroth and John Spertus.

2 sessions

Part 5

Meet The Expert: Implications for Clinical Practice - Breakout 3

Age groups and vulnerable patients with Gerasimos Filippatos and Giuseppe Rosano.

3 sessions

Part 6

State of the Art 2

6 sessions

Part 7

SGLT2 Inhibitors for Heart Failure: The New Standard of Care

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

3 sessions

  • Welcome and Introduction

    Watch now
  • Keynote Lecture - SGLT2 Inhibitors for Heart Failure: The New Standard of Care

    Watch now
  • Panel Discussion

    Watch now

Part 8

Meet The Expert: Implications for Clinical Practice - Breakout 4

Early Treatment Initiation in the Hospital Setting - discussion with Marc Petrie and Deepak Bhatt. Session supported by an unrestricted grant from AstraZeneca

3 sessions

Part 9

Meet The Expert: Implications for Clinical Practice - Breakout 5

Managing Patients with Comorbidities (T2D & CKD) - discussion with Paola Fioretto and Katherine Tuttle. Session supported by an unrestricted grant from AstraZeneca

1 session

  • Managing Patients with Comorbidities (T2D & CKD)

    Watch now

Part 10

Meet The Expert: Implications for Clinical Practice - Breakout 6

Interdisciplinary Collaboration and Care Transitions - discussion with Subodh Verma. Session supported by an unrestricted grant from AstraZeneca

1 session

  • Interdisciplinary Collaboration and Care Transitions

    Watch now

Faculty biographies